What question did this study set out to answer?

The research aims to assess the resistance to bictegravir and lenacapavir in individuals undergoing treatment.

March 26, 2026Open Access

Baseline and week 48 resistance analysis in participants receiving bictegravir + lenacapavir in the phase 2 ARTISTRY-1 study

NPNina PennetzdorferGilead Sciences (United States)VNVidula NaikGilead Sciences (United States)JMJairo M. Montezuma-RuscaGilead Sciences (United States)

Key Points

The research aims to assess the resistance to bictegravir and lenacapavir in individuals undergoing treatment.
Conducted resistance analysis at baseline and week 48
Monitored participants receiving bictegravir and lenacapavir
Evaluated rates of viral suppression
High frequencies of baseline resistance observed
Substantial rates of viral suppression maintained through week 48
No on-treatment resistance to study drugs detected

Abstract

Despite high frequencies of baseline resistance, substantial rates of viral suppression were maintained through Week 48 and no on-treatment resistance to study drugs was detected. These findings support the development of once-daily BIC + LEN STR to improve and optimize treatment options in individuals on complex ART.

AI से पूछें

Bookmark

View Full Paper